Previous close | 327.18 |
Open | 324.60 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 324.60 - 327.95 |
52-week range | 246.30 - 335.60 |
Volume | |
Avg. volume | 389,242 |
Market cap | N/A |
Beta (5Y monthly) | 0.15 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malariaMalaria is a serious and potentially fatal parasitic infection most commonly transmitted by mosquitoes that can also be spread through blood transfusionRoche is dedicated to saving patients’ lives through diagnostic solutions that aid in the protection of the global blood supply from infectious diseases Basel, 26 March 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. Food and
All proposals of the Board of Directors approvedSeverin Schwan re-elected as Chairman of the Board of Directors; all other Board members standing for election confirmed37th consecutive dividend increase to CHF 9.60 per share Basel, 12 March 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its shareholders had approved all proposals of the Board of Directors at its Annual General Meeting. The 635 shareholders in attendance, who represented 77.02% of the total 106,691,000 shares, app
Roche (SIX: RO, ROG; OTCQX: RHHBY) introduces navify Analytics, its suite of cloud-based solutions that provide actionable insights to optimise operational and financial outcomes in laboratories and point of care (POC) settings. navify Analytics for POC will make its debut at the HIMSS 2024 Conference in Orlando, USA, from 11-15 March 2024.